|Application ||WB, IHC-P, FC, E|
|Calculated MW||19171 Da|
|Antigen Region||119-147 aa|
|Other Names||Anterior gradient protein 3 homolog, AG-3, AG3, hAG-3, Breast cancer membrane protein 11, AGR3, BCMP11|
|Target/Specificity||This AGR3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 119-147 amino acids from the C-terminal region of human AGR3.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||AGR3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Required for calcium-mediated regulation of ciliary beat frequency and mucociliary clearance in the airway. Might be involved in the regulation of intracellular calcium in tracheal epithelial cells.|
|Cellular Location||Endoplasmic reticulum Note=Found in the cytoplasm, which could include the endoplasmic reticulum.|
|Tissue Location||Expressed in the lung, in the ciliated cells of the airway epithelium (PubMed:25751668). Expression increased with differentiation of airway epithelial cells (PubMed:25751668) Not detected in the mucous cells (PubMed:25751668). Expressed in ciliated cells in the oviduct (PubMed:26170690). Also detected in stomach, colon, prostate and liver (PubMed:25751668). Expressed in breast, ovary, prostate and liver cancer (PubMed:26170690) Expression is associated with the level of differentiation of breast cancer (at protein level) (PubMed:26170690)|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
AGR3 (Anterior Gradient 3) protein, also known as AG3 (hAG3, HAG3 in human), or BCMP11, is a secreted cytoplasmic protein which is involved in metastasis induction and p53 tumour supressor inhibition. It may serve as molecular marker and potential therapeutic target for hormone-responsive breast tumours. Its Xenopus homolog is associated with anteroposterior fate determination during early development.
Persson, S., et al. Mol. Phylogenet. Evol. 36(3):734-740(2005)
Zhang, Z., et al. Protein Sci. 13(10):2819-2824(2004)
Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
Fletcher, G.C., et al. Br. J. Cancer 88(4):579-585(2003)
Adam, P.J., et al. J. Biol. Chem. 278(8):6482-6489(2003)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.